KTTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pasithea Therapeutics Corp (KTTA) is not a strong buy for a beginner, long-term investor at this time. While the company has a promising pipeline and a positive analyst rating, its financial performance is weak, and there are no clear technical or trading signals to support an immediate entry. The lack of significant news, trading trends, and influential activity further suggests a wait-and-see approach.
The MACD is above 0 and positively contracting, indicating mild bullish momentum. RSI is neutral at 63.462, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level of 0.871, which could limit further upside in the short term.
The company has a next-generation MEK inhibitor targeting a $20B market, with a 'Buy' rating and a $3 price target from H.C. Wainwright. This indicates long-term growth potential.
Weak financial performance in Q3 2025, including a net income loss of -$3,037,420 and a significant EPS drop of -85.71% YoY. No recent news, significant trading trends, or influential activity to support a bullish case.
In Q3 2025, the company reported no revenue growth, a net income loss of -$3,037,420 (up 1.25% YoY), and an EPS drop of -85.71% YoY. Gross margin remains at 0%.
H.C. Wainwright initiated coverage with a 'Buy' rating and a $3 price target, citing the company's promising pipeline targeting a $20B market. However, no other analyst updates or ratings are available.
